overview
given
develop
technolog
allow
revers
genet
rna
virus
ie
rescu
virus
cdna
emphasi
nonseg
negativestrand
rna
virus
mononegaviral
exemplifi
measl
viru
mv
primarili
technolog
allow
sitedirect
mutagenesi
enabl
import
insight
varieti
aspect
biolog
virus
concomitantli
foreign
code
sequenc
insert
allow
local
viru
replic
vivo
marker
gene
express
b
develop
candid
multival
vaccin
measl
pathogen
c
creat
candid
oncolyt
virus
vector
use
virus
experiment
encourag
pronounc
genet
stabil
recombin
unexpect
rna
virus
high
load
insert
genet
materi
excess
kb
known
asset
small
genom
size
vector
comparison
dna
virus
propos
vector
extens
clinic
experi
attenu
mv
vaccin
proven
record
high
safeti
efficaci
low
product
cost
per
vaccin
dose
thu
favor
complement
revers
genet
ie
introduct
exactli
defin
mutat
genom
organ
true
live
organ
virus
becom
one
technic
cornerston
molecular
biolog
conveni
applic
import
techniqu
rna
virus
reli
possibl
rescu
virus
clone
dna
repres
sequenc
variant
rna
genom
underli
dna
segment
easili
obtain
basic
revers
transcript
vitro
manipul
even
conveni
synthes
chemic
econom
amplifi
bacteria
segment
resid
within
plasmid
primari
drive
forc
establish
revers
genet
system
rna
virus
obtain
insight
biolog
inde
investig
use
tool
bring
wealth
knowledg
regard
propag
virus
interact
host
addit
recogn
earli
revers
genet
technolog
might
also
exploit
practic
purpos
medicin
creat
new
vaccin
possibl
also
combat
cancer
take
advantag
strong
often
longlast
stimul
immun
system
virus
particularli
promis
use
attenu
virus
alreadi
wide
proven
medic
practic
constitut
effici
safe
vaccin
parent
wildtyp
progenitor
addit
genom
genet
materi
encod
protein
protein
fragment
import
pathogen
might
result
multival
vaccin
mediat
protect
viru
speci
use
vector
also
pathogen
ad
genet
inform
deriv
three
decad
sinc
great
progress
made
gradual
make
essenti
rna
viru
genera
amen
applic
revers
genet
last
decad
process
obtain
genet
modifi
virus
revers
genet
refin
facilit
technic
process
practic
desir
construct
rna
viru
made
readili
avail
provid
chang
introduc
compat
effici
propag
construct
cultur
cell
packag
infecti
viral
particl
outlin
manipul
plusstrand
rna
virus
obtain
rather
easili
among
problemat
negativestrand
rna
virus
contain
nonseg
genom
ie
one
group
larg
order
mononegaviral
difficult
get
hold
repres
contain
segment
genom
bacteriophag
qbeta
first
viru
techniqu
could
appli
case
rescu
viru
particularli
easi
clone
dna
segment
repres
sequenc
viral
genom
simpli
flank
oligo
stretch
transcrib
spontan
introduct
escherichia
coli
cell
resid
rna
polymeras
sinc
intracellularli
transcrib
genom
first
activ
messeng
rna
produc
viral
protein
subsequ
templat
viral
rna
polymerasereplicas
produc
antigenom
progeni
genom
transcrib
progeni
viru
form
automat
still
clear
mechan
primari
transcript
contain
addit
nonvir
flank
sequenc
give
rise
progeni
rna
contain
precis
viral
end
next
viru
made
amen
revers
genet
poliomyel
viru
racaniello
baltimor
experiment
hurdl
overcom
consider
higher
case
cultur
host
cell
much
demand
b
genom
clone
approxim
twice
long
c
necessari
provid
promot
resid
dnadepend
rna
polymeras
nevertheless
due
key
properti
similar
outlin
qbeta
progeni
viru
could
rescu
spontan
introduct
either
properli
construct
dna
vitro
transcrib
rna
host
cell
pioneer
work
trigger
rescu
larg
varieti
plusstrand
rna
virus
infect
vertebr
invertebr
plant
microorgan
even
coronavirus
largest
rna
virus
genom
excess
kb
amen
genet
manipul
similar
experiment
techniqu
could
employ
positivestrand
rna
virus
despit
vastli
differ
propag
mechan
attenu
poliomyel
viru
also
first
rna
viru
employ
vector
creat
plurival
vaccin
candid
introduct
foreign
genet
materi
andino
et
al
vector
use
positivestrand
rna
virus
suffer
howev
two
major
drawback
one
hand
size
introduc
code
sequenc
limit
space
constraint
icosahedr
viral
capsid
hand
addit
sequenc
introduc
often
surviv
origin
form
viral
gener
particularli
evid
qbeta
rna
bacteriophag
elimin
andor
modifi
ad
alter
sequenc
incred
fast
rate
underli
reason
strict
requir
suitabl
secondari
tertiari
rna
structur
optim
rna
replic
notori
errorpron
rnadepend
rna
polymeras
usual
defin
replicas
rna
structur
paramount
import
plusstrand
rna
virus
genom
activ
state
insid
host
cell
nake
loos
associ
protein
particular
delet
introduc
transcript
recombin
due
copychoic
transcript
come
detach
replicas
associ
incomplet
transcript
templat
reattach
templat
preferenti
locat
complementari
last
nucleotid
transcript
sinc
rna
virus
delet
nonessenti
genom
region
replic
rapidli
spontan
mutant
soon
overgrow
origin
construct
genom
despit
drawback
genet
stabil
recombin
virus
appear
suffici
practic
applic
particular
alphaviru
flaviviru
vector
promis
part
advanc
clinic
trial
among
former
semliki
forest
sindbi
venezuelan
equin
enceph
virus
mention
atkin
et
al
tubuleka
et
al
polo
et
al
pushko
et
al
among
latter
yellow
fever
viru
base
licens
attenu
vaccin
strain
arroyo
et
al
monath
et
al
brandler
et
al
seem
particularli
promis
two
distinct
featur
negativestrand
rna
virus
render
inher
difficult
rescu
clone
dna
genom
complementari
sens
strand
activ
messeng
rna
produc
viral
protein
mere
function
templat
requir
format
initi
mrna
transcript
step
subsequ
antigenom
rna
replic
step
act
templat
synthesi
genom
rna
replic
step
transcript
replic
mediat
viral
rnadepend
rna
polymeras
also
defin
transcriptasereplicas
transcript
step
character
format
less
fulllength
transcript
typic
cap
polyadenyl
wherea
replic
step
unmodifi
fulllength
transcript
synthes
genom
rna
biolog
activ
present
ribonucleoprotein
rnp
ie
associ
least
nucleocapsid
protein
call
n
np
viral
rna
polymeras
word
minim
infecti
unit
consist
mere
rna
specif
associ
complex
rnp
case
highli
segment
virus
influenza
virus
polymeras
compos
three
polypeptid
mononegaviral
consist
one
larg
polypeptid
l
frequent
associ
phosphoprotein
p
fulfil
multipl
function
addit
role
polymeras
cofactor
particular
chaperon
mediat
attach
n
genom
antigenom
rna
synthes
thu
rescu
viru
clone
dna
necessari
deliv
rnp
host
cell
one
two
approach
vitromad
transcript
must
function
cover
vitro
viral
protein
mention
introduct
host
cell
altern
transcript
one
hand
encapsid
protein
larg
quantiti
viral
rna
polymeras
tini
amount
hand
concomitantli
synthes
host
cell
form
biolog
activ
rnp
almost
two
decad
ago
first
partial
rescu
negativestrand
rna
viru
clone
dna
describ
luytj
et
al
enami
et
al
sinc
rnp
segment
negativestrand
rna
virus
structur
rel
loos
artifici
vitro
transcript
one
clone
segment
influenza
viru
strain
x
could
encapsid
vitro
protein
requir
rnp
format
nucleocapsid
three
larg
polypeptid
form
togeth
viral
rna
polymeras
vitroform
rnp
introduc
cell
infect
influenza
viru
strain
use
helper
viru
reassort
influenza
viru
could
isol
contain
seven
segment
helper
viru
one
segment
deriv
strain
x
howev
method
requir
separ
small
number
reassort
away
larg
excess
nonreassort
helper
viru
achiev
mean
specif
antibodi
direct
protein
encod
segment
strain
replac
although
work
constitut
first
breakthrough
area
also
permit
gener
interest
design
influenza
viru
mutant
experiment
limit
sinc
necess
counterselect
step
restrict
rang
rescuabl
manipul
construct
one
decad
intens
work
sever
group
requir
elabor
method
enabl
rescu
influenza
viru
entir
dna
ie
without
helper
viru
neumann
et
al
fodor
et
al
method
use
larg
array
simultan
cotransfect
plasmid
specifi
eight
antigenom
rna
well
mrna
product
protein
requir
rnp
format
allow
rescu
practic
desir
influenza
viru
compat
requir
biolog
properti
class
virus
preparatori
work
use
minireplicon
numer
research
group
attempt
invari
fail
assembl
vitro
rnp
mononegaviral
follow
modifi
lesson
provid
initi
account
describ
rescu
influenza
viru
three
main
reason
failur
first
foremost
rnp
mononegaviral
much
tighter
rigid
segment
influenza
viru
inde
contrast
latter
complet
resist
rnase
digest
second
rna
genom
cover
much
longer
one
influenza
segment
encapsid
origin
influenza
viru
rescu
procedur
third
extrem
larg
multidomain
rna
polymeras
l
mononegaviral
prone
nonfunct
aggreg
three
subunit
influenza
enzym
consequ
mani
investig
reason
genom
antigenom
mononegaviral
encapsid
insid
cultur
cell
statu
nascendi
ie
synthes
artifici
cdna
templat
foreign
dnadepend
rna
polymeras
express
host
cell
inde
soon
success
rescu
influenza
virus
first
step
toward
rescu
mononegaviral
achiev
rna
minireplicon
certain
member
viral
order
trigger
clone
dna
propag
variou
cell
line
dna
underli
minireplicon
initi
deriv
revers
transcript
natur
defect
interf
particl
di
gener
spontan
mononegaviral
propag
serial
success
high
infect
rate
later
minireplicon
dna
construct
minim
contain
noncod
signal
sequenc
essenti
virusspecif
rna
replic
viral
gene
either
partial
complet
delet
replac
report
gene
conveni
detect
virusspecif
transcript
replic
collin
et
al
collin
et
al
park
et
al
conzelmann
schnell
sidhu
et
al
investig
use
two
kind
helper
virus
provid
protein
intracellularli
encapsid
replic
minireplicon
simpl
approach
vitro
transcript
small
clone
dna
segment
introduc
cell
infect
cognant
parent
nondefect
viru
advanc
strategi
dna
specifi
minireplicon
transfect
along
dna
encod
encapsid
protein
nucleocapsid
n
phosphoprotein
p
larg
polymeras
l
requir
format
biolog
activ
rnp
cell
infect
vaccinia
viru
construct
engin
express
rna
polymeras
high
level
dna
contain
promot
thu
strategi
allow
effici
transcript
virusspecif
clone
dna
segment
transfect
cell
obvious
goal
experi
find
optim
condit
achiev
replic
much
longer
genom
fulllength
nondefect
virus
isol
spuriou
amount
assembl
rescu
virus
away
helper
virus
present
larg
quantiti
first
achiev
rabi
viru
rv
use
almost
ident
technic
approach
approxim
year
later
two
group
abl
rescu
vesicular
stomat
viru
vsv
lawson
et
al
whelan
et
al
rv
vsv
belong
famili
rhabdovirida
member
character
sturdi
bulletshap
virion
structur
highli
effici
vigor
replic
achiev
high
viral
titer
furthermor
replicationpropag
scarc
inhibit
helper
viru
thu
tini
amount
rescu
viru
could
isol
seri
elabor
purif
step
includ
passag
filter
rescu
reli
exclus
transfect
dna
although
pioneer
work
describ
previou
section
establish
function
rnp
entir
genom
mononegaviral
inde
form
intracellularli
approach
necessarili
fail
rescu
measl
viru
mv
repres
famili
paramyxovirida
contain
larger
genom
replic
titer
order
magnitud
lower
rv
vsv
form
larg
polyploid
virion
easili
inactiv
chemic
physic
stress
filtrat
therefor
appear
desir
develop
rescu
method
avoid
helper
virus
altogeth
thu
obviat
need
purif
step
achiev
reli
transfect
plasmid
encod
n
p
protein
well
rna
polymeras
transcript
artifici
mrna
govern
strong
cmv
promot
recogn
cellular
rna
polymeras
ii
resid
nuclei
rather
promot
intron
polyadenyl
sequenc
transcrib
region
plasmid
insert
ensur
cap
splice
polyadenyl
thu
enabl
effici
export
cytoplasm
well
long
halflif
mrna
clear
despit
precaut
express
plasmid
would
allow
much
weaker
express
rna
polymeras
achiev
howev
strategi
chosen
plasmid
encod
viral
protein
n
p
requir
larg
quantiti
reli
promot
procedur
enabl
rescu
rhabdovirida
thu
rel
low
level
rna
polymeras
thought
suffici
synthesi
antigenom
rna
mrna
encod
larg
viral
polymeras
requir
tini
amount
mention
maxim
chanc
success
initi
approach
involv
two
separ
step
employ
first
helper
cell
stabli
transfect
three
plasmid
endow
cmv
promot
encod
three
protein
n
p
rna
polymeras
plasmid
encod
rna
polymeras
contain
neomycin
neo
resist
marker
among
approxim
neoresist
coloni
two
chosen
propag
line
helper
cell
addit
rna
polymeras
express
n
p
appreci
level
helper
cell
line
still
use
today
sever
research
group
second
helper
cell
transient
transfect
two
plasmid
contain
promot
one
specifi
precis
initi
termin
minireplicon
later
fulllength
antigenom
transcript
use
small
amount
encod
larg
viral
rna
polymeras
l
approach
trigger
high
level
chloramphenicol
acetyl
transferas
cat
cell
transfect
artifici
minireplicon
dna
bear
cat
report
gene
similar
level
obtain
introduc
vitro
transcript
cat
minireplicon
dna
mvinfect
cell
experi
success
longer
viral
antigenom
region
ad
minireplicon
sequenc
give
rise
term
midireplicon
expect
cat
signal
elicit
becam
weaker
increas
midireplicon
size
final
miss
antigenom
sequenc
ad
lead
end
first
rescu
mv
clonal
deriv
singl
syncytia
thu
constitut
addit
benefit
comparison
rescu
use
helper
viru
yield
mixtur
differ
clone
see
fig
viru
denomin
mv
edtag
tag
three
nucleotid
exchang
nontransl
region
distinguish
parent
attenu
vaccinederiv
mv
edmonston
b
type
strain
passag
extens
mani
laboratori
howev
took
month
patent
applic
file
almost
year
first
origin
research
paper
publish
sinc
experiment
procedur
verifi
differ
collabor
genet
stabil
rescu
virus
ascertain
ad
marker
gene
even
chimera
construct
envelop
protein
mv
genet
substitut
uniqu
envelop
protein
anoth
viru
vsv
spielhof
spielhof
et
al
comment
regard
rescu
procedur
gener
necessari
might
appear
odd
artifici
express
antigenom
rather
genom
rna
sinc
requir
replic
step
yield
genom
rnp
transcript
produc
viral
mrna
subsequ
viral
protein
take
place
howev
sever
research
group
independ
adopt
strategi
circumv
hybrid
thu
inactiv
artifici
express
antigenom
larg
amount
artifici
express
mrna
encod
n
p
soon
public
rv
rescu
socal
viru
construct
base
modifi
viru
ankara
mva
strain
vaccinia
viru
use
helper
cell
clone
cell
stabli
transfect
express
plasmid
encod
rna
polymeras
n
p
protein
note
intracellular
antigenom
transcript
specifi
p
mv
type
plasmid
start
precis
antigenom
end
cleav
automat
hepat
ribozym
sequenc
termin
termin
signal
b
slightli
modifi
rescu
protocol
simultan
transfect
cell
cell
line
support
replic
mv
use
exactli
five
plasmid
use
origin
method
plasmid
pn
pp
util
gener
cell
clone
c
similar
method
b
use
highli
effici
chicken
actin
ca
promot
rather
cytomegaloviru
cmv
promot
martin
et
al
recombin
express
rna
polymeras
level
similar
produc
previous
avail
helper
viru
importantli
howev
mva
variant
replic
certain
point
mammalian
cell
form
progeni
viru
avian
cell
thu
use
defect
helper
viru
circumv
elimin
progeni
helper
viru
second
mean
rescu
larg
major
construct
mononegaviral
obtain
origin
procedur
enabl
rescu
rhabdovirida
inde
shortli
public
independ
methodolog
describ
rescu
human
respiratori
syncyti
viru
rsv
employ
report
collin
et
al
numer
public
describ
rescu
differ
genera
mononegaviral
method
actual
variant
rhabdoviru
rescu
procedur
appear
account
mention
complex
method
loos
similar
rv
vsv
rescu
procedur
employ
complet
differ
purif
approach
applic
rescu
sendai
viru
sev
particular
repres
paramyxovirida
publish
garcin
et
al
concurr
first
rescu
rsv
collin
et
al
worth
note
howev
method
base
vacciniaderiv
helper
viru
regardless
whether
form
progeni
rescu
procedur
suffer
sever
import
drawback
import
high
rate
recombin
induc
vaccinia
viru
among
transfect
plasmid
lead
frequent
incorpor
sequenc
resid
plasmid
encod
n
p
protein
antigenom
plasmid
thu
rescu
viru
therefor
sever
profici
investig
field
later
switch
procedur
similar
one
describ
exclus
use
express
plasmid
thu
circumv
need
helper
viru
first
publish
account
line
use
rescu
bovin
rsv
buchholz
et
al
context
also
mention
curious
even
yusuk
yanagi
group
describ
protocol
rescu
wildtyp
mv
strain
tatsuo
et
al
base
replic
profici
strain
also
use
origin
rescu
rv
howev
note
yanagi
group
use
particular
cell
line
shown
earlier
suitabl
isol
wildtyp
mv
strain
acut
infect
individu
marmoset
b
cell
deriv
line
express
slam
receptor
exclus
use
wildtyp
mv
strain
cell
line
helper
viru
replic
exceedingli
slowli
form
small
number
progeni
thu
experiment
condit
close
resembl
use
replicationdefici
helper
viru
discuss
preced
paragraph
advantag
modif
origin
method
mv
rescu
involv
gradual
shift
use
persist
transfect
helper
cell
transient
transfect
cell
line
modif
particularli
advantag
new
viral
speci
rescu
clone
cdna
sinc
circumv
tediou
select
cellular
clone
express
addit
rna
n
p
protein
new
viral
speci
suitabl
ratio
standard
cell
line
abl
support
replic
new
viru
transfect
simultan
five
requir
plasmid
see
fig
note
mv
rescu
exact
origin
transient
transfect
procedur
util
vari
inclus
three
plasmid
express
rna
polymeras
viral
protein
n
p
origin
setup
alreadi
present
persist
transfect
helper
cell
rescu
effici
use
onestep
transient
transfect
higher
origin
method
enhanc
instead
cmv
promot
chicken
actin
promot
martin
et
al
use
compar
fig
c
principl
first
adopt
rescu
mump
viru
clark
et
al
later
mani
manipul
repres
mononegaviral
describ
great
experiment
detail
recent
intern
patent
applic
wo
addit
simplif
mv
rescu
recent
describ
util
cmv
promot
antigenom
express
plasmid
recogn
nuclear
polymeras
ii
rather
tradit
promot
martin
et
al
reason
tri
strategi
actual
dictat
borna
viru
bv
rescu
bv
replic
nucleu
therefor
reason
test
pol
pol
ii
promot
latter
prove
optim
find
strategi
also
success
mv
suggest
mv
rnp
form
nucleu
concomitantli
synthesi
antigenom
rna
pol
ii
thu
imped
splice
fortuit
splice
site
rnp
reach
cytoplasm
rather
effici
rnp
format
nucleu
appear
like
attribut
fact
n
protein
artifici
express
alon
migrat
effici
nucleu
huber
et
al
like
also
carri
along
associ
chaperon
p
protein
simultan
express
mention
one
major
drive
forc
behind
develop
system
enabl
revers
genet
mononegaviral
gain
better
insight
biolog
repres
viral
order
comprehens
illustr
mv
chapter
book
sinc
chapter
mainli
deal
possibl
practic
applic
enabl
techniqu
first
design
artifici
mutant
mv
mention
first
modif
consist
larg
delet
nucleotid
almost
entir
untransl
region
utr
f
gene
gcrich
cell
cultur
mutant
show
deterior
propag
experi
anim
model
describ
chapter
ferret
cotton
rat
transgen
mice
macaqu
conduct
date
might
demonstr
delet
region
inde
dispens
viabil
infect
model
anim
thu
like
also
human
note
howev
human
thymusliv
implant
engraft
scid
mice
mutant
replic
somewhat
slowli
viru
titer
reach
roughli
ten
time
lower
parent
mv
edtag
valsamaki
et
al
also
f
gene
repres
genu
morbilliviru
rel
long
utr
exist
although
none
compar
length
recent
region
well
preced
long
utr
gene
reexamin
differ
cell
line
conclud
former
decreas
f
protein
product
thu
inhibit
mv
replic
reduc
cytopathogen
wherea
latter
increas
product
promot
viru
replic
takeda
et
al
one
specul
f
protein
predecessor
mv
might
much
longer
shorter
function
version
f
protein
aros
remain
untransl
region
rather
elimin
would
dictat
maxim
compact
genet
materi
rna
virus
becam
target
bias
gi
hypermut
cattaneo
et
al
bass
et
al
result
replac
u
c
residu
genom
type
massiv
mutat
alter
observ
frequent
defect
gene
mv
trigger
subacut
scleros
panenceph
sspe
cattaneo
et
al
cattaneo
et
al
cattaneo
billet
mainten
superflu
sequenc
mv
might
somewhat
realist
hypothesi
view
virtual
absenc
recombin
copi
choic
obligatori
adher
rule
six
hallmark
repres
subfamili
paramyxovirina
discuss
rule
see
follow
chapter
anoth
sitedirect
mutat
inactiv
c
read
frame
p
gene
radeck
billet
mutant
propag
normal
vero
cell
like
due
absenc
interferon
type
respons
cell
view
support
later
studi
sendai
viru
show
ablat
ctype
protein
lead
heavili
compromis
virus
sinc
sendai
ctype
protein
interfer
interferon
respons
addit
protein
involv
transcriptionrepl
delenda
et
al
garcin
et
al
garcin
et
al
garcin
et
al
garcin
et
al
mv
cmutant
replic
poorli
human
peripher
blood
cell
pbmc
escoffi
et
al
well
human
thymusliv
implant
scid
mice
valsamaki
et
al
suggest
role
c
protein
also
transcript
replic
mv
ablat
mv
edtag
v
protein
aris
natur
occur
attenu
mv
strain
cotranscript
edit
cattaneo
et
al
overexpress
v
show
impair
interferondefici
vero
cell
line
schneider
et
al
pbmc
escoffi
et
al
suggest
v
essenti
requir
transcriptionrepl
interestingli
vmutant
multipli
slowli
v
overexpress
mutant
rapidli
parent
viru
human
implant
scid
mice
valsamaki
et
al
furthermor
cand
vmutant
appear
overattenu
sinc
multipli
poorli
ifnar
ko
transgen
mice
express
devoid
interferon
type
respons
mrkic
et
al
howev
result
must
interpret
caution
mv
edtag
strain
ctermin
portion
v
protein
deviat
p
protein
alreadi
defect
begin
replac
import
amino
acid
conserv
approv
mv
vaccin
strain
combredet
et
al
recent
studi
wildtyp
mv
deriv
lack
v
c
macaqu
indic
defect
mv
replic
less
extens
restrict
interferon
inflammatori
respons
wherea
antibodi
mvspecif
cell
respons
equal
wildtyp
variant
virus
devaux
et
al
function
matrix
protein
address
either
elimin
read
frame
naim
et
al
replac
frame
mv
edtag
hypermut
read
frame
recov
brain
deceas
sspe
patient
patterson
et
al
mutant
virus
abl
replic
albeit
slowli
cultur
polar
cell
line
deriv
lung
epithelia
well
brain
transgen
mice
express
primari
brain
cell
cultur
experi
also
show
migrat
coloc
n
envelop
protein
f
h
particular
cell
compart
depend
naim
et
al
directli
demonstr
interact
nucleocapsid
one
hand
cytoplasm
tail
envelop
protein
also
replac
mv
envelop
protein
studi
direct
mutat
mv
strain
replac
singl
amino
acid
h
protein
wildtyp
mv
abl
use
slam
cell
entri
also
gain
abil
util
gener
second
receptor
recogn
attenu
vaccin
strain
erlenhof
et
al
f
protein
shown
singl
replac
leu
posit
aikc
vaccin
strain
phe
typic
schwarzmoraten
strain
result
enhanc
syncytium
format
distinguish
featur
two
vaccin
strain
nakayama
et
al
addit
transcript
unit
atu
insert
rather
easili
mv
antigenom
sequenc
place
short
sequenc
stretch
embrac
intergen
region
nontransl
region
resid
mv
gene
addit
cassett
uniqu
restrict
site
present
plasmid
bear
antigenom
mv
sequenc
allow
insert
foreign
read
frame
see
fig
overview
care
taken
final
construct
obey
rule
six
state
number
nucleotid
genom
terminu
integr
multim
six
ie
genom
precis
cover
n
molecul
contact
six
nucleotid
rule
first
found
valid
sev
copyback
minireplicon
calain
roux
construct
intern
deletionreplac
mv
minireplicon
sidhu
et
al
later
adher
rule
shown
strict
requir
fulllength
recombin
mv
well
rager
et
al
parainfluenzaviru
type
skiadopoulo
et
al
like
imper
repres
viral
subfamili
paramyxovirina
whenev
antigenom
cdna
construct
deviat
mutat
rule
virus
rescu
bear
second
mutat
prefer
close
first
one
correct
deviat
addit
atu
insert
first
p
h
gene
also
n
gene
hangartn
zuniga
et
al
recent
also
l
gene
del
vall
et
al
two
approach
express
addit
foreign
code
sequenc
also
explor
aim
ensur
insert
read
frame
remain
function
intact
ie
mutat
without
inactiv
recombin
viru
particular
gener
virus
contain
prematur
stop
codon
errorpron
viral
rna
polymeras
repeat
viral
passag
avoid
one
approach
foreign
read
frame
link
downstream
resid
mv
read
frame
stoprestart
signal
overlap
stop
codon
adjac
initi
codon
ugaug
featur
influenza
b
virus
express
downstream
ns
read
frame
second
approach
protein
selfcleavag
featur
foot
mouth
diseas
viru
adopt
hangartn
wang
et
al
c
three
differ
stain
pattern
one
syncytium
shown
induc
triport
mv
contain
egfp
orf
betagalactosidas
lacz
orf
posit
cat
orf
posit
zuniga
et
al
link
upstream
foreign
code
region
downstream
mv
code
region
stretch
nucleotid
gener
short
polypeptid
abl
cleav
almost
exactli
upstream
mv
protein
ryan
drew
design
transgen
protein
bear
ctermin
elong
amino
acid
wherea
mv
protein
bear
singl
foreign
amino
acid
nterminu
approach
insert
place
upstream
l
gene
express
low
level
first
method
lead
rescuabl
virus
wherea
second
approach
work
might
actual
employ
particular
case
l
martin
unpublish
result
howev
sinc
larg
varieti
recombin
mv
mutat
format
prematur
stop
codon
found
actual
problem
approach
explor
practic
least
time
conveni
insert
read
frame
encod
variou
marker
protein
monitor
locat
mv
replic
cell
variou
primari
cell
type
infect
model
anim
cell
line
organ
infect
anim
furthermor
function
insert
atu
readili
ascertain
read
frame
encod
marker
conveni
replac
code
sequenc
medic
relev
frequent
use
marker
apart
luciferas
shown
fig
also
illustr
insert
site
level
express
frequent
use
marker
green
fluoresc
protein
gfp
variou
deriv
spielhof
duprex
et
al
duprex
et
al
naim
et
al
numer
public
mention
mv
recombin
express
marker
use
larg
varieti
purpos
sinc
gfp
readili
diffus
away
site
product
sever
attempt
made
incorpor
gfp
viral
protein
directli
visual
locat
viral
assembl
insert
strongli
express
mv
protein
yield
reason
viabl
virus
rather
surprisingli
one
insert
larg
polymeras
l
success
express
cytokin
mainli
act
adjuv
enhanc
immunogen
vaccin
use
variou
system
mv
far
employ
attempt
complet
elimin
immunosuppress
hallmark
wildtyp
mv
infect
also
character
vaccin
strain
extent
function
express
high
level
insert
contain
code
region
two
compon
separ
intern
ribosom
entri
site
howev
macaqu
recombin
viru
fail
elimin
immunosuppress
although
humor
cellular
immun
respons
alter
hoffman
et
al
read
frame
encod
protein
pathogen
usual
insert
mv
context
replac
marker
gene
describ
mv
either
singl
multipl
insert
construct
shown
exampl
fig
zuniga
et
al
recombin
show
replic
properti
cell
line
similar
parent
empti
mv
usual
speed
propag
slightli
delay
end
titer
reach
purpos
vaccin
product
slight
delay
counterproduct
vaccin
host
delay
propag
might
result
consider
reduc
immunogen
vaccin
howev
could
counterbalanc
growth
plot
function
infecti
virus
releas
yaxi
time
xaxi
experiment
condit
describ
previous
wang
et
al
zuniga
et
al
clone
posit
antigen
illustr
lower
panel
abbrevi
tag
parent
empti
tag
mv
without
atu
mv
singl
atu
contain
siv
fulllength
anchor
envelop
orf
polymeras
posit
atu
siv
env
groupspecif
antigen
gag
capsid
protein
orf
posit
gag
mv
atu
contain
siv
envelop
orf
posit
siv
capsid
orf
posit
muvmv
singl
atu
contain
mump
viru
hemagglutininneuraminidas
orf
posit
use
higher
viral
dose
given
approv
mv
vaccin
administ
low
dose
rang
plaqu
form
unit
would
perfectli
feasibl
practic
multipl
insert
gener
lead
slowli
grow
recombin
singl
insert
posit
insert
length
qualiti
express
addit
protein
much
import
insert
posit
upstream
n
gene
delay
particularli
long
glycoprotein
target
endoplasm
reticulum
er
usual
problemat
protein
remain
cytoplasm
furthermor
membraneanchor
glycoprotein
deleteri
excret
one
probabl
tend
compet
mv
envelop
protein
nevertheless
one
instanc
mv
insert
deriv
mump
viru
muv
test
replic
delay
toler
practic
applic
like
due
competit
mv
muv
glycoprotein
assembl
viral
particl
wang
et
al
evid
fig
initi
slow
propag
recombin
express
muv
h
later
resum
speed
similar
empti
mv
howev
rapidli
grow
viru
turn
lost
muv
h
express
obvious
qualiti
mv
backbon
paramount
import
viabil
thu
immunogen
recombin
vivo
mention
mv
edtag
mutat
alter
thu
expos
interferon
type
respons
mutat
v
mention
mainli
p
cv
l
gene
might
also
crippl
viru
test
ifnar
ko
mice
mrkic
et
al
receptor
inactiv
recombin
base
laboratori
strain
replic
effici
reason
immunogen
howev
macaqu
even
high
dose
strain
poorli
immunogen
contrast
licens
schwarz
vaccin
strain
elicit
strong
humor
cellmedi
immun
respons
combredet
et
al
kept
mind
prior
none
publish
vaccin
studi
cite
mv
recombin
base
licens
vaccin
strain
use
today
two
group
see
lorin
et
al
del
vall
et
al
use
recombin
base
schwarzmoraten
strain
obtain
differ
sourc
must
recal
sequenc
schwarz
moraten
strain
ident
despit
report
differ
attenu
regimen
park
et
al
park
et
al
convers
vector
base
licens
edmonston
zagreb
ez
vaccin
strain
develop
employ
sever
studi
hy
naim
et
al
unpublish
result
pathogen
address
recombin
mv
describ
publish
report
address
individu
addit
varieti
project
underway
address
among
other
malaria
human
papilloma
viru
hpv
avian
influenza
viru
hepat
b
viru
hbv
first
pathogen
candid
mvbase
vaccin
develop
recombin
express
small
surfac
antigen
hbsag
prove
genet
stabl
least
ten
serial
viral
transfer
criterion
subsequ
check
routin
recombin
candid
vaccin
induc
strong
humor
immun
respons
ifnar
ko
mice
recombin
insert
encod
surfac
core
antigen
differ
cassett
singl
mv
vector
also
shown
express
protein
howev
project
discontinu
sinc
develop
new
hbv
vaccin
deem
commerci
promis
given
effici
vaccin
hbv
alreadi
exist
attenu
mv
vaccin
effici
infant
age
month
wherea
develop
countri
chronic
hbvinfect
mother
usual
transfer
viru
newborn
nevertheless
differ
laboratori
recent
mvvector
hbv
vaccin
candid
express
hbsag
construct
del
vall
et
al
insert
use
previous
place
mv
schwarzderiv
vector
p
h
l
gene
ifnar
ko
mice
recombin
induc
antibodi
expect
vector
p
l
cassett
elicit
highest
lowest
immunogen
respect
macaqu
two
four
anim
inocul
p
cassett
vector
gener
humor
anti
respons
conclud
optim
immun
respons
insert
antigen
import
choos
strongest
express
compat
reason
high
replic
speed
mv
recombin
repeat
vaccin
recombin
primeboost
regimen
use
either
protein
adjuv
viral
vector
adopt
noteworthi
recombin
protect
macaqu
effici
challeng
wildtyp
mv
commerci
vaccin
might
specul
optim
mvvector
hbv
vaccin
could
even
use
therapeut
larg
number
chronic
hbvinfect
patient
present
mainli
southeast
asia
target
studi
use
mv
vector
aid
arguabl
import
infecti
diseas
vaccin
exist
yet
due
favor
record
attenu
mv
term
efficaci
safeti
discuss
elsewher
book
also
next
princip
chapter
mvvector
vaccin
among
strongest
candid
final
success
aid
first
mvbase
attempt
aid
involv
siv
antigen
wang
et
al
two
laboratori
varieti
differ
read
frame
encod
gag
pol
env
nef
deriv
siv
hiv
sinc
insert
either
isol
directli
manipul
variou
way
eg
resynthes
consensu
sequenc
delet
andor
fusion
view
high
variabl
hiv
particularli
env
manipul
differ
way
get
rid
highli
variabl
region
thu
expos
mainli
conserv
epitop
interest
earli
studi
anchor
env
appear
prefer
excret
form
induc
neutral
antibodi
sever
heterolog
hiv
primari
isol
elicit
cellmedi
immun
respons
lorin
et
al
noteworthi
observ
hbv
vaccin
mv
preimmun
prevent
antihiv
immun
respons
reveal
fig
sever
recent
review
potenti
mv
vector
vaccin
gener
particular
aid
discuss
tangi
naim
zuniga
et
al
among
human
diseas
caus
member
famili
flavivirida
yellow
fever
japanes
enceph
dengu
fever
west
nile
wn
fever
import
effici
vaccin
exist
first
two
morbid
lethal
caus
diseas
still
high
western
africasouth
america
asiapacif
region
respect
contrast
vaccin
avail
latter
two
thu
recent
review
wn
dengu
fever
address
use
mvschwarz
strain
mvschw
vector
exodomain
flavivirus
similar
structur
highli
immunogen
thu
rather
express
anchor
glycoprotein
case
candid
aid
vaccin
region
encod
exodomain
flavivirus
insert
mv
first
western
nile
viru
wnv
address
effici
infect
mice
peripher
inocul
caus
lethal
neuroinvas
diseas
similar
enceph
human
secret
form
glycoprotein
e
se
express
low
dose
mvschwsewnv
protect
mice
lethal
challeng
wnv
least
period
rang
day
month
vaccin
despr
et
al
current
unpublish
experi
efficaci
recombin
also
demonstr
primat
model
squirrel
monkey
saimiri
sciureu
complet
protect
wnv
singledos
vaccin
dengu
viru
dv
pose
greater
problem
four
serotyp
exist
expos
portion
gpe
fold
three
globular
ectodomain
ed
ii
iii
outermost
immunoglobulinlik
ed
iii
fold
independ
singl
disulfid
bond
determin
serotyp
specif
contain
major
neutral
epitop
thu
announc
tangi
group
construct
encod
four
ediii
domain
dv
insert
mvschw
vector
immunogen
studi
ongo
immedi
follow
sar
epidem
fear
sar
corona
viru
cov
might
use
bioterror
nucleocapsid
protein
n
codonoptim
spike
glycoprotein
sarscov
insert
independ
posit
p
gene
mv
edtag
yield
p
mvsarsn
p
sarss
mvsuscept
ifnar
ko
mice
recombin
induc
high
antibodi
titer
n
antibodi
gener
sexpress
mv
strongli
neutral
sarscov
mv
nexpress
mv
elicit
cellular
immun
respons
measur
elispot
also
case
preimmun
empti
mv
impair
immun
respons
sar
cov
mixtur
two
recombin
induc
respons
similar
magnitud
singl
vaccin
linig
et
al
project
develop
recombin
mv
cancer
extens
discuss
elsewher
book
see
chapter
russel
et
al
volum
mention
oncolyt
virus
construct
rescu
basic
recombin
discuss
oncolyt
properti
mv
recogn
earli
find
mv
infect
resolv
burkitt
lymphoma
blume
ziegler
enhanc
properti
numer
alter
introduc
mv
deriv
vaccin
intent
retarget
recombin
specif
cancer
cell
ablat
interact
known
mv
receptor
slam
thu
primarili
h
read
frame
manipul
creat
slightli
shorten
h
protein
carri
ctermini
ligand
fit
onto
differ
receptor
express
abundantli
divers
type
cancer
cell
first
promis
recombin
creat
author
recent
review
von
messl
cattaneo
later
origin
public
see
springfeld
et
al
ungerecht
et
al
ungerecht
et
al
one
interest
develop
concern
manipul
mv
recent
creation
mv
contain
bior
even
tripartit
genom
denomin
segmv
segmv
respect
takeda
et
al
dna
construct
underli
segment
virus
design
bear
precis
termin
untransl
region
present
parent
mv
addit
mv
gene
segmv
could
accommod
six
addit
transcript
unit
effici
express
five
encod
protein
demonstr
importantli
express
long
insert
encod
betagalactosidas
place
upstream
n
gene
segment
compris
mv
n
p
gene
impair
replic
recombin
much
less
betagalactosidas
resid
posit
monopartit
mv
suggest
long
multipl
insert
could
express
effici
segment
mv
use
vector
surprisingli
effici
propag
explain
fact
mv
particl
grown
cell
line
larg
polyploid
rager
et
al
contain
far
one
genom
addit
rel
short
genom
replic
probabl
replicas
quit
templat
prematur
lower
long
templat
segment
mv
use
evalu
practic
much
addit
experiment
need
first
attenu
licens
mv
vaccin
strain
use
rather
wildtyp
isol
construct
deriv
second
rescu
method
use
employ
exclus
transfect
plasmid
rather
helper
viru
third
construct
tripartit
viru
segment
contain
one
gene
requir
replic
n
p
l
ideal
fulli
exploit
potenti
segment
mv
vector
one
segment
bear
one
short
transgen
upstream
measl
gene
encod
f
h
l
wherea
two
segment
encod
n
p
respect
could
bear
multipl
rel
long
insert
upand
downstream
mv
gene
fourth
propag
immunogen
anim
model
check
comparison
monopartit
mv
vector
proviso
mean
reduc
import
pioneer
work
rna
polymeras
known
much
errorpron
dna
polymeras
due
lack
proofread
thu
error
rate
rna
virus
averag
approxim
three
order
magnitud
higher
dna
virus
socal
quasispeci
concept
rna
virus
explor
earli
studi
bacteriophag
qbeta
domingo
et
al
therefor
came
great
surpris
find
mv
recombin
transgen
rather
stabli
express
although
nonessenti
case
deleteri
viru
propag
expect
even
rapidli
mutat
mv
gene
conserv
posit
select
express
first
transgen
studi
mv
encod
chloramphenicol
acetyl
transferas
cat
insert
p
h
gene
complet
maintain
analyz
progeni
clone
deriv
singl
origin
rescu
clone
ten
serial
viru
passag
repres
amplif
factor
spielhof
howev
experi
clone
deriv
second
rescu
clone
serial
transfer
parallel
lost
cat
express
seem
like
error
alreadi
occur
second
origin
rescu
clone
transcript
particularli
errorpron
rna
polymeras
almost
later
rescu
recombin
transgen
express
maintain
express
muvderiv
transgen
encod
muv
f
hn
lost
result
virus
propag
fast
empti
mv
wherea
freshli
rescu
recombin
slow
discuss
shown
fig
none
case
transgen
express
lost
could
delet
detect
monitor
pcr
suggest
recombin
copychoic
must
extrem
rare
event
contrast
plusstrand
rna
virus
readili
delet
insert
foreign
sequenc
copychoic
event
must
occur
sometim
mv
gener
defect
interf
particl
di
aris
fashion
howev
di
copyback
type
polymeras
leav
origin
templat
togeth
unfinish
transcript
attach
transcript
rather
origin
templat
virtual
absenc
delet
event
must
due
extrem
tight
rnp
structur
render
reattach
replicas
templat
anoth
posit
almost
imposs
misincorpor
singl
nucleotid
certainli
occur
mv
appreci
extent
document
nucleotid
chang
characterist
posit
attenu
process
obtain
vaccin
strain
park
et
al
park
et
al
loss
virul
upon
passag
wildtyp
viru
isol
nonlymphoid
cell
kobun
et
al
tatsuo
et
al
howev
case
mutat
chang
result
propag
advantag
cell
use
attenu
thu
select
origin
viru
contrast
loss
express
protein
interfer
viral
propag
neutral
nevertheless
surpris
ablat
protein
express
could
easili
aris
nucleotid
exchang
lead
prematur
stop
codon
thu
interrupt
code
region
document
singl
nucleotid
delet
insert
could
also
lead
truncat
express
protein
virtual
exclud
due
strict
adher
mv
paramyxovirina
rule
six
discuss
missens
mutat
transgen
obvious
difficult
detect
nonsens
mutat
knowledg
none
insert
mv
event
exclud
sequenc
ten
standard
serial
viral
transfer
howev
long
antigen
properti
express
protein
sever
hamper
case
chang
expect
deterior
recombin
vaccin
slightli
efficaci
vaccin
use
attenu
mv
quit
remark
vaccine
seroconvert
protect
life
least
clinic
manifest
mv
infect
present
hope
mvexpress
singl
antigen
pathogen
elicit
compar
strong
durabl
protect
nevertheless
encourag
first
instanc
protect
anim
model
close
human
test
case
mv
express
exodomain
wnv
gpe
complet
protect
month
document
monkey
mention
clinic
trial
recombin
vaccin
candid
base
mv
plan
stage
thu
practic
success
still
await
year
come
view
sever
costli
hurdl
impos
regulatori
agenc
nevertheless
potenti
mv
recombin
effici
multival
vaccin
start
appreci
increas
number
vaccin
expert
even
particularli
difficult
case
malaria
elicit
sever
differ
variabl
strain
plasmodium
complet
protect
expect
mv
recombin
might
elicit
immun
respons
compar
trigger
first
plasmodium
infect
everi
infant
subsaharan
africa
contract
would
alreadi
import
success
sinc
first
infect
respons
death
caus
malaria
wherea
plasmodium
infect
involv
much
less
morbid
impact
mv
recombin
aid
might
consid
less
optimist
sinc
partial
protect
vaccin
would
like
result
increas
neglig
protect
measur
mv
compar
vaccin
regimen
base
deliveri
genet
materi
comparison
plasmid
dna
efficaci
expect
much
higher
term
safeti
certainli
favor
danger
integr
genet
materi
human
genom
neglig
comparison
deliv
dna
dna
virus
expect
appear
valid
despit
report
integr
cdna
deriv
lymphocyt
choriomening
viru
lcmv
mous
genom
klenerman
et
al
addit
advantag
rel
small
size
mv
comparison
dna
virus
use
deliveri
vehicl
protein
vector
express
addit
express
artifici
insert
thu
minim
superflu
immun
respons
fact
immun
respons
vector
must
also
consid
benefici
least
long
mv
erad
goal
take
mani
year
achiev
might
never
reach
mention
opinion
medic
expert
mv
vaccin
africa
attenu
mv
vaccin
gener
benefici
develop
immun
system
infant
therefor
maintain
even
measl
erad
one
day
comparison
rna
viru
vector
high
genet
stabil
mv
noteworthi
share
repres
viral
subfamili
paramyxovirina
repres
adher
rule
six
wherea
mononegaviral
somewhat
less
stabl
addit
high
possibl
payload
insert
unrestrict
viral
capsid
structur
note
consequ
mv
vaccin
replicationcompet
replicationdefici
vector
dna
virus
use
rna
viru
vector
base
alphavirus
broadli
consid
gener
safer
howev
replicationdefici
entail
two
major
drawback
one
hand
dose
higher
mani
order
magnitud
comparison
replic
vehicl
deliv
even
importantli
rang
action
limit
onestep
infect
cell
bear
suitabl
viru
receptor
place
deliveri
possibl
contrast
significantli
attenu
mv
vaccin
owe
high
efficaci
system
spread
preferenti
infect
profession
antigenpres
cell
lymphoid
tissu
case
mv
replic
compet
appear
advantag
term
safeti
efficaci
sinc
mv
vaccin
extrem
good
safeti
record
mv
vaccin
recommend
even
immunocompromis
patient
eg
hiv
sever
sequela
wildtyp
mv
infect
sspe
stop
vaccin
importantli
cell
target
mv
recombin
alter
transgen
envelop
protein
except
mvrelat
glycoprotein
muv
envelop
shown
incorpor
mv
particl
wang
et
al
quit
gener
noteworthi
kill
vaccin
subunit
vaccin
necessarili
safer
replicationcompet
vaccin
shown
kill
mv
vaccin
prove
lack
efficaci
even
exacerb
effect
subsequ
wildtyp
mv
infect
thu
gener
increas
gradient
safeti
one
compar
replicationcompet
versu
replicationrestrict
versu
dead
vaccin
compon
deliv
human
must
plan
develop
evalu
equal
care
without
priori
bia
base
theoret
gener
illus
classif
danger
human
health
preimmun
concern
use
recombin
mv
vaccin
given
almost
adolesc
adult
individu
immun
measl
due
prior
wildtyp
mv
infect
mv
vaccin
b
matern
antibodi
measl
young
infant
month
age
prevent
immun
attenu
mv
vaccin
therefor
vaccin
recombin
mv
initi
consid
exclus
young
infant
age
mv
vaccin
recommend
thu
replac
standard
vaccin
bior
multival
vaccin
protect
measl
also
import
diseas
malaria
regimen
certainli
still
prefer
option
care
taken
ascertain
anim
model
variou
transgen
mv
hamper
immunogen
measl
del
vall
et
al
howev
measl
immun
boost
children
preimmun
first
vaccin
particularli
boost
given
aerosol
bennett
et
al
thu
probabl
wrong
assum
immun
reaction
measl
young
infant
immun
system
still
immatur
necessarili
similar
older
children
adult
sinc
exampl
mvbase
aid
vaccin
given
much
later
sexual
activ
begin
import
ascertain
time
anim
model
preimmun
vaccin
standard
mv
vaccin
prevent
boost
recombin
mv
fact
boost
result
enhanc
immun
respons
mv
induct
immun
respons
transgen
del
vall
et
al
see
fig
nevertheless
effici
boost
mv
recombin
probabl
wane
increas
number
boost
thu
primeboost
regimen
use
either
subunit
vaccin
adjuv
deliveri
viral
vector
may
advantag
practic
adenoviru
vector
induc
immun
respons
newborn
alreadi
might
close
gap
mv
vaccin
use
particularli
attract
regimen
might
entail
vector
base
attenu
muv
similar
mv
use
wide
human
vaccin
furthermor
vector
base
mononegaviral
among
preferenti
belong
paramyxovirina
also
consid
repres
genera
belong
subfamili
thu
far
unclassifi
virus
might
explor
crossreact
genera
exist
howev
attenu
mv
muv
virus
extens
experi
human
exist
therefor
prefer
option
vector
use
particularli
sinc
abl
least
principl
induc
lifelong
immun
sad
progress
toward
new
vaccin
improv
exist
vaccin
block
sever
slow
issu
base
scientif
technic
consider
true
gener
one
exampl
failur
improv
sabin
vaccin
polio
plan
mutat
would
imped
revers
wildtyp
virus
repeatedli
led
small
epidem
impedi
highli
regrett
case
mv
similar
virus
vector
use
appear
promis
battl
import
diseas
vaccin
develop
basi
vector
may
particularli
enhanc
public
mrkic
et
al
preimmun
tcid
mv
edtag
month
later
twice
tcid
recombin
mv
contain
hiv
envelop
glycoprotein
posit
right
panel
two
cynomolgu
macaqu
preimmun
standard
human
vaccin
dose
tcid
commerci
rouvax
mv
immun
month
recombin
util
mice
use
tcid
lorin
et
al
tangi
naim
health
develop
countri
consid
reason
outlin
low
cost
product
per
vaccin
dose
great
import
human
health
high
level
respons
expect
regulatori
agenc
fda
unit
state
fulli
recogn
nevertheless
difficult
understand
case
polio
vaccin
mention
preced
section
phase
iii
clinic
trial
cost
hundr
million
dollar
would
impos
even
appli
minor
chang
would
render
vaccin
much
safer
one
blame
manufactur
refrain
improv
product
view
enorm
cost
entail
similarli
impos
extens
costli
clinic
trial
might
warrant
recombin
base
wide
use
mv
vaccin
provid
rigor
demonstr
addit
express
antigen
toxic
cell
target
recombin
viru
alter
insert
transgen
immun
respons
gener
measl
tradit
mv
vaccin
manufactur
process
practic
use
tradit
vaccin
might
also
ask
whether
societi
gener
accept
prevail
principl
ethic
behavior
ie
maxim
averag
benefit
largest
possibl
number
individu
risk
accompani
everi
human
invent
mani
case
traffic
sport
activ
risk
tacitli
accept
case
vaccin
rare
advers
effect
medic
activ
compound
routin
explain
leaflet
accompani
drug
usual
toler
admittedli
vaccin
must
consid
differ
administ
healthi
individu
particularli
children
nevertheless
even
highli
advers
effect
vaccin
accept
long
effect
remain
rare
sever
morbid
death
prevent
larg
popul
factbas
nonemot
dialogu
scientist
societi
clearli
necessari
possibl
find
accept
legal
procedur
solut
similar
problem
even
though
present
gener
right
individu
prevail
right
commun
unfortun
patent
unavoid
actual
produc
base
scientif
endeavor
either
academ
corpor
research
laboratori
medic
valuabl
commerci
product
competit
compani
scientist
import
drive
forc
may
consid
benefici
detriment
long
run
howev
develop
mononegaviral
vaccin
vector
mani
research
differ
laboratori
invent
tool
indispens
success
establish
revers
genet
foreign
gene
express
instanc
competit
financi
avid
among
compani
also
among
scientist
sever
hamper
progress
patent
offic
must
necessarili
adher
legal
consider
research
institut
amen
compromis
base
recognit
scientif
merit
patent
conflict
costli
demotiv
gener
becom
intoler
exampl
scientif
collabor
arisen
mani
year
subsid
public
grant
money
unilater
discontinu
decre
institut
director
forc
research
financi
benefit
institut
discontinu
flow
materi
inform
discuss
variou
section
varieti
mononegaviral
rescu
dna
first
report
rescu
number
virus
address
excel
gener
review
paramyxovirida
interact
host
lamb
park
list
includ
rabv
vsv
lawson
et
al
whelan
et
al
mv
human
respiratori
viru
hrsv
collin
et
al
sev
garcin
et
al
kato
et
al
rinderpest
viru
baron
barrett
durbin
et
al
hoffman
banerje
et
al
ndv
peeter
et
al
brsv
buchholz
et
al
exampl
foreign
gene
insert
paramyxovirida
report
review
parainfluenza
virus
compris
genera
respiroviru
rubulaviru
avulaviru
karron
collin
backbon
bear
f
hn
gene
rather
bovin
counterpart
schmidt
et
al
hpiv
intern
protein
gene
n
p
replac
bovin
counterpart
skiadopoulo
et
al
candid
vaccin
human
parainfluenza
addit
foreign
gene
deriv
virus
hrsv
human
metapneumoviru
hmpv
also
insert
schmidt
et
al
skiadopoulo
et
al
well
sev
vector
base
repres
genu
avulaviru
newcastl
diseas
viru
ndv
offici
call
appear
promis
vaccin
oncolyt
agent
veterinarian
human
use
ge
et
al
lorenc
et
al
dinapoli
et
al
estevez
et
al
vigil
et
al
jank
et
al
drawback
respirovirus
vaccin
vector
even
full
infect
nonattenu
virus
protect
reinfect
agent
thu
protect
attenu
respiroviru
vector
expect
longlast
two
main
genera
lyssaviru
vesiculoviru
recent
review
rhabdovirida
lyle
rupprecht
rabi
viru
rabv
two
main
subtyp
vsv
indiana
new
jersey
propos
vaccin
vector
mainli
aid
therapeut
agent
rose
et
al
schnell
et
al
palin
et
al
simon
et
al
clark
et
al
bergman
et
al
diaz
et
al
brandsma
et
al
schwartz
et
al
tani
et
al
cooper
et
al
rabv
particularli
vsv
deriv
recombin
contain
insert
advantag
replic
extrem
high
titer
sinc
natur
host
vsv
cattl
hors
swine
mosquito
sandfli
human
use
somewhat
problemat
particularli
sinc
vsv
show
neurovirul
primat
johnson
et
al
howev
vsv
greatli
attenu
shuffl
gene
wertz
et
al
comparison
mononegaviral
particular
vsv
mv
vector
lag
behind
evid
recent
publish
report
cite
preced
section
part
may
stem
rel
low
titer
obtain
mv
preexist
immun
mv
adolesc
adult
human
popul
discuss
suboptim
andor
expens
anim
model
clinic
studi
involv
mv
vector
vaccin
applic
plan
phase
present
ongo
oncolyt
mv
recombin
requir
less
strict
previou
test
thu
promis
recombin
mv
vaccin
obtain
studi
anim
model
yet
corrobor
human
uniqu
mv
host
nevertheless
varieti
reason
discuss
chapter
predict
search
medic
applic
recombin
mv
rapidli
gain
momentum
suggest
recent
review
compar
differ
viral
vector
vaccin
purpos
brave
et
al
comparison
vector
base
rna
virus
mv
gener
mononegaviral
appear
clearli
superior
hope
present
attach
vector
gradual
wane
occur
mani
dna
viru
applic
deliv
plasmid
dna
compar
studi
clearli
need
studi
compar
replic
restrict
replicationcompet
vector
thought
superior
least
case
mv
muv
